Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma

Exclusion Criteria

• •Patients \<12 years of age or the minimum legal age for adolescents in the country of the investigative site, whichever is higher (for those countries where local regulations permit enrollment of adults only, patient recruitment will be restricted to those who are ≥18 years of age).
• •Weight is less than 30 kg at the screening visit (Visit 1) or the randomization visit (Visit 2).
• •Chronic obstructive pulmonary disease or other lung diseases (eg, idiopathic pulmonary fibrosis) which may impair lung function.
• •A patient who experiences a severe asthma exacerbation (defined as deterioration of asthma that results in emergency treatment, hospitalization due to asthma, treatment with systemic steroids, or treatment with systemic steroid at least twice the previous dose for patients on OCS maintenance) at any time from 1 month prior to the screening visit (Visit 1) up to and including the randomization visit (Visit 2).
• •Evidence of lung disease(s) other than asthma, either clinical or imaging evidence (eg, chest X-ray, computed tomography, and magnetic resonance imaging) within 3 months prior to the screening visit (Visit 1) as per local standard of care.
• •Current smoker or cessation of smoking within 6 months prior to the screening visit (Visit 1).
• •Previous smoker with a smoking history \>10 pack-years.
• •Comorbid disease that might interfere with the evaluation of investigational medicinal product (IMP).
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.